NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Fulcrum Therapeutics, Inc. FULC
8 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-1.18
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-25.3%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 8-year series below
Revenue
Net income
Per share
USD -1.18
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-25.3%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-23.9%
Each USD of equity lost 25 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.07B
Shares outstanding, FY2025
Change, 5 years+138.3%
Change, 10 years—
The share count grew 138% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 366.3M
total assets, end of FY2025
Total assetsUSD 366.3M
EquityUSD 349.0M
CashUSD 197.5M
Current ratio27.40×
Equity funds 95% of total assets.
History
8 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
Revenue $B
0.0
0.1
0.0
0.0
0.0
0.0
·
·
Operating income $B
−0.1
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
EBITDA $B
−0.1
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
Income tax $B
0.0
0.0
·
·
·
·
·
·
Net income $B
−0.1
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
EPS, diluted $
−1.18
−0.16
−1.59
−2.44
−2.29
−2.79
−8.13
−31.14
Dividend / sh $
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
ROE %
−25.3
−4.1
−44.8
−53.5
−52.7
−77.7
−704.1
·
Shares out B
0.07
0.05
0.06
0.05
0.04
0.03
0.02
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
24 of 24
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed